[go: up one dir, main page]

RU2004126950A - Использование выделяющих co соединений при изготовлении лекарственного средства для лечения воспалительных заболеваний - Google Patents

Использование выделяющих co соединений при изготовлении лекарственного средства для лечения воспалительных заболеваний Download PDF

Info

Publication number
RU2004126950A
RU2004126950A RU2004126950/14A RU2004126950A RU2004126950A RU 2004126950 A RU2004126950 A RU 2004126950A RU 2004126950/14 A RU2004126950/14 A RU 2004126950/14A RU 2004126950 A RU2004126950 A RU 2004126950A RU 2004126950 A RU2004126950 A RU 2004126950A
Authority
RU
Russia
Prior art keywords
disease
compound
inflammatory
component
class
Prior art date
Application number
RU2004126950/14A
Other languages
English (en)
Inventor
Вернер ХААС (PT)
Вернер ХААС
Карлуш РОМАО (PT)
Карлуш РОМАО
Беатрис РОЙО (PT)
Беатрис РОЙО
Ана Кристина ФЕРНАНДЕС (PT)
Ана Кристина ФЕРНАНДЕС
Изабель ГОНСАЛВЕС (PT)
Изабель ГОНСАЛВЕС
Original Assignee
АЛФАМА-Инвестигасау и Дезенволвименту де Продутош Фармасеутикуш Лда. (PT)
АЛФАМА-Инвестигасау и Дезенволвименту де Продутош Фармасеутикуш Лда.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by АЛФАМА-Инвестигасау и Дезенволвименту де Продутош Фармасеутикуш Лда. (PT), АЛФАМА-Инвестигасау и Дезенволвименту де Продутош Фармасеутикуш Лда. filed Critical АЛФАМА-Инвестигасау и Дезенволвименту де Продутош Фармасеутикуш Лда. (PT)
Publication of RU2004126950A publication Critical patent/RU2004126950A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F17/00—Metallocenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/603—Salicylic acid; Derivatives thereof having further aromatic rings, e.g. diflunisal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/32—Manganese; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/52—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F11/00—Compounds containing elements of Groups 6 or 16 of the Periodic Table
    • C07F11/005—Compounds containing elements of Groups 6 or 16 of the Periodic Table compounds without a metal-carbon linkage
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
    • C07F13/005—Compounds without a metal-carbon linkage
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/02—Iron compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (28)

1. Способ предотвращения и/или лечения заболевания млекопитающего, включающий в себя этап назначения к указанному млекопитающему соединения, способного выделять СО in vivo при самопроизвольном или метаболическом процессе.
2. Способ по п.1, отличающийся тем, что указанное соединение содержит компонент с СО.
3. Способ по п.2, отличающийся тем, что указанное соединение выбрано из следующих классов:
класса 1 - содержащих СО металлоорганических комплексов;
класса 2 - содержащих СО металлоорганических комплексов, связанных по меньшей мере с другой фармакологически эффективной молекулой;
класса 3 - надмолекулярных агрегатов из содержащих СО металлоорганических комплексов;
класса 4 - содержащих СО неорганических комплексов с лигандами из числа доноров N и/или S, функционирующих в качестве обратимых переносчиков СО;
класса 5 - содержащих СО, связанных по меньшей мере с другой фармакологически эффективной молекулой неорганических комплексов с лигандами из числа доноров N и/или S, функционирующих в качестве обратимых переносчиков СО;
4. Способ по п.1, отличающийся тем, что указанное соединение содержит компонент, способный вырабатывать СО in vivo.
5. Способ по п.4, отличающийся тем, что указанное соединение выбрано из следующих классов:
класса 6 - органических веществ, выделяющих СО или при ферментативном процессе или при декарбонилировании.
класса 7 - органических веществ, выделяющих СО или при ферментативном процессе или при декарбонилировании.
6. Способ по п.1, отличающийся тем, что указанное соединение, способное выделять СО, содержит по меньшей мере компонент, выделяющий СО, и переносчик и/или вторую фармацевтически эффективную молекулу.
7. Способ по п.6, отличающийся тем, что вторая фармацевтически эффективная молекула представляет собой противовоспалительный агент.
8. Способ по п.7, отличающийся тем, что указанный противовоспалительный агент является ингибитором циклооксигеназы или ингибитором фосфодиэстеразы.
9. Способ по п.8, отличающийся тем, что указанный ингибитор циклооксигеназы выбран из группы, включающей в свой состав аспирин, нимезулид и напроксен.
10. Способ по п.6, отличающийся тем, что указанная вторая фармацевтически эффективная молекула представляет собой бифосфонат или производное бифосфоната.
11. Способ по п.1, отличающийся тем, что указанное заболевание представляет собой воспалительное заболевание, заболевание с сильным воспалительным компонентом, астму, трамву, инфаркт, болезнь, протекающую с расстройством кровообращения.
12. Способ по п.11, отличающийся тем, что указанное заболевание с сильным воспалительным компонентом представляет собой атеросклероз, инсульт, ишемическую болезнь сердца и болезнь Альцгеймера.
13. Способ по п.11, отличающийся тем, что указанное воспалительное заболевание является хроническим воспалительным заболеванием типа ревматоидного артрита.
14. Способ по п.1, отличающийся тем, что указанное млекопитающее является человеком.
15. Соединение для предотвращения и/или лечения заболевания млекопитающего, способное выделять СО in vivo при самопроизвольном или метаболическом процессе и содержащее по меньшей мере компонент, выделяющий СО, и вторую фармацевтически эффективную молекулу.
16. Соединение по п.15, отличающееся тем, что содержит также соответствующее промежуточное звено, связывающее указанный компонент, выделяющий СО, и указанную вторую фармацевтически эффективную молекулу.
17. Соединение по п.15, отличающееся тем, что указанная вторая фармацевтически эффективная молекула представляет собой переносчик лекарственного вещества или лекарственное вещество.
18. Соединение по п.17, отличающийся тем, что лекарственное вещество представляет собой противовоспалительный агент.
19. Соединение по п.18, отличающееся тем, что указанный противовоспалительный агент является ингибитором циклооксигеназы или ингибитором фосфодиэстеразы.
20. Соединение по п.19, отличающееся тем, что указанный ингибитор циклооксигеназы выбран из группы, включающей в свой состав аспирин, нимезулид и напроксен.
21. Соединение по п.17, отличающееся тем, что указанное лекарственное вещество представляет собой производное бифосфоната или бифосфонат.
22. Соединение по п.15, отличающееся тем, что указанный компонент, выделяющий СО, представляет собой металлоорганический комплекс.
23. Соединение по п.15, отличающееся тем, что указанный компонент, выделяющий СО, представляет собой неорганический комплекс.
24. Соединение для предотвращения и/или лечения воспалительных заболеваний, являющееся соединением по п.15.
25. Лекарственный препарат, содержащий соединение по п.15.
26. Лекарственный препарат по п.25, отличающийся тем, что указанный состав предназначен для предотвращения и/или лечения воспалительного заболевания или заболевания с сильным воспалительным компонентом, астмы, трамвы, инфаркта, болезни, протекающей с расстройством кровообращения.
27. Лекарственный препарат по п.26, отличающийся тем, что указанное воспалительное заболевание представляет собой хроническое воспалительное заболевание типа ревматоидного артрита.
28. Лекарственный препарат по п.26, отличающийся тем, что указанное заболевание с сильным воспалительным компонентом представляет собой ревматоидный артрит, атеросклероз, инсульт, ишемическую болезнь сердца и болезнь Альцгеймера.
RU2004126950/14A 2002-02-04 2003-02-03 Использование выделяющих co соединений при изготовлении лекарственного средства для лечения воспалительных заболеваний RU2004126950A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35323302P 2002-02-04 2002-02-04
US60/353,233 2002-02-04

Publications (1)

Publication Number Publication Date
RU2004126950A true RU2004126950A (ru) 2005-06-27

Family

ID=27734286

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2004126950/14A RU2004126950A (ru) 2002-02-04 2003-02-03 Использование выделяющих co соединений при изготовлении лекарственного средства для лечения воспалительных заболеваний

Country Status (11)

Country Link
US (4) US7011854B2 (ru)
EP (3) EP1476168A2 (ru)
JP (1) JP2005519928A (ru)
CN (1) CN1646140A (ru)
AU (2) AU2003208525B9 (ru)
BR (1) BR0307420A (ru)
CA (1) CA2475209A1 (ru)
NZ (1) NZ534912A (ru)
RU (1) RU2004126950A (ru)
WO (1) WO2003066067A2 (ru)
ZA (1) ZA200406711B (ru)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8128963B2 (en) * 1996-09-27 2012-03-06 The Trustees Of Columbia University In The City Of New York Methods for treating ischemic disorders using carbon monoxide
US7678390B2 (en) * 1999-04-01 2010-03-16 Yale University Carbon monoxide as a biomarker and therapeutic agent
US20040014099A1 (en) * 2001-03-19 2004-01-22 Decode Genetics Ehf. Susceptibility gene for human stroke; methods of treatment
GB0111872D0 (en) 2001-05-15 2001-07-04 Northwick Park Inst For Medica Therapeutic agents and methods
EP2033514A3 (en) * 2001-06-21 2009-04-29 Beth Israel Deaconess Medical Center, Inc. Carbon Monoxide Improves Outcomes in Cell and Organ Transplants and Suppresses Apoptosis
US7968605B2 (en) * 2002-02-04 2011-06-28 ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda. Methods for treating inflammatory disease by administering aldehydes and derivatives thereof
NZ534912A (en) * 2002-02-04 2007-08-31 Alfama Investigacao E Desenvol supramolecule aggregate comprising CO containing organometallic or transition metal complex and anti-inflammatory agent or biphosphonate phosphonate derivative
US20080026984A1 (en) * 2002-02-04 2008-01-31 Alfama - Investigacao E Desenvolvimento De Productos Farmaceuticos Lda Methods for treating inflammatory disease by administering aldehydes and derivatives thereof
SG148850A1 (en) * 2002-02-13 2009-01-29 Beth Israel Hospital Methods of treating vascular disease
MXPA04010242A (es) * 2002-04-15 2005-06-08 Univ Pittsburgh Metodos para tratar enterocolitis necrotizante.
EP1499186A4 (en) 2002-04-15 2009-10-28 Beth Israel Hospital USE OF HEME-OXYGENASE-1 AND HEME DEGRADATION PRODUCTS
PL373002A1 (en) * 2002-04-15 2005-08-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Methods of treating ileus
DK1505990T3 (da) * 2002-05-17 2011-11-21 Univ Yale Fremgangsmåder til behandling af hepatitis
EA200401622A1 (ru) * 2002-06-05 2005-06-30 Йейл Юниверсити Способы лечения ангиогенеза, роста опухолей и метастазов
CA2504604A1 (en) * 2002-11-07 2004-05-27 Timothy R. Billiar Treatment for hemorrhagic shock
GB2395432B (en) * 2002-11-20 2005-09-14 Northwick Park Inst For Medica Therapeutic delivery of carbon monoxide to extracorporeal and isolated organs
US7813440B2 (en) 2003-01-31 2010-10-12 Ntt Docomo, Inc. Multiple-output multiple-input (MIMO) communication system, MIMO receiver and MIMO receiving method
WO2005013691A1 (en) * 2003-08-04 2005-02-17 Hemocorm Limited Use of boranocarbonates for the therapeutic delivery of carbon monoxide
US7462405B2 (en) * 2003-12-05 2008-12-09 Eastman Kodak Company Organic element for electroluminescent devices
WO2005085870A1 (en) * 2004-03-03 2005-09-15 The Charlotte-Mecklenburg Hospital Authority The use of free hemoglobin and its surrogate markers to detect and monitor pulmonary hypertension
CA2560212A1 (en) * 2004-03-18 2005-09-22 Ibet-Instituto De Biologia Experimental E Tecnologica Compositions comprising organometallic molybdenum compounds for treating cancer
WO2007073226A1 (en) * 2005-12-20 2007-06-28 Alfama - Investigação E Desenvolvimento De Produtos Farmacêuticos Lda Method for treating a mammal by administration of a compound having the ability to release co
WO2007073225A1 (en) * 2005-12-20 2007-06-28 Alfama - Investigação E Desenvolvimento De Produtos Farmacêuticos Lda. Molybdenum carbonyl complexes for treating rheumatoid arthritis and other inflammatory diseases
GB0601394D0 (en) * 2006-01-24 2006-03-01 Hemocorm Ltd Therapeutic delivery of carbon monoxide
DE102006020492A1 (de) * 2006-04-21 2007-10-25 Novalung Gmbh Verwendung von Acetylsalicylsäure (ASS) beim Einsatz einer Membranlunge
GB0613362D0 (en) 2006-07-05 2006-08-16 Hemocorm Ltd Therapeutic delivery of carbon monoxide
AU2007328549A1 (en) * 2006-12-06 2008-06-12 Alfama - Investigacao E Desenvolvimento De Produtos Farmaceuticos Lda Methods for treating inflammatory disease by administering aldehydes and derivatives thereof
WO2008080128A1 (en) * 2006-12-22 2008-07-03 The Board Of Regents Of The University Of Texas System Devices and methods for inhibiting fibrosis
RU2331441C1 (ru) * 2006-12-27 2008-08-20 Институт прикладной механики УрО РАН Гипергазированное и гиперосмотическое антисептическое средство
JP2010525055A (ja) * 2007-04-24 2010-07-22 アルファーマ−インベスティガシオ エ デセンボルビメント デ プロデュトス ファルマセウティコス エレデア． 一酸化炭素による感染症の処置
US20110038955A1 (en) * 2007-07-24 2011-02-17 Alfama - Investigacao E Desenvolvimento De Produtos Farmaceuticos, Lda. Prevention of gastric ulcer by carbon monoxide
WO2011110315A1 (en) 2010-03-08 2011-09-15 University Of Zurich Carbon monoxide releasing rhenium compounds for medical use
DE102010014412A1 (de) * 2010-04-08 2012-04-19 Friedrich-Schiller-Universität Jena Verwendung von zweikernigen Eisenkomplexen mit schwefelhaltigen Liganden als pharmakologische Wirkstoffe
CN103491783A (zh) * 2011-01-14 2014-01-01 洛杉矶儿童医院 用于治疗包括镰状细胞疾病的疾病的一氧化碳溶液
US8927750B2 (en) 2011-02-04 2015-01-06 Universitaet Zu Koeln Acyloxy- and phosphoryloxy-butadiene-Fe(CO)3 complexes as enzyme-triggered co-releasing molecules
KR101398368B1 (ko) 2011-03-16 2014-05-22 울산대학교 산학협력단 일산화탄소 또는 일산화탄소 공급체를 유효성분으로 포함하는 폐경기 증상의 예방 또는 치료용 조성물
ES2656237T3 (es) * 2011-04-19 2018-02-26 Alfama, Inc. Moléculas liberadoras de monóxido de carbono y usos de las mismas
WO2013013179A1 (en) 2011-07-21 2013-01-24 Alfama, Inc. Ruthenium carbon monoxide releasing molecules and uses thereof
CN102850403B (zh) * 2012-05-29 2015-01-14 嘉兴学院 一种水溶性铁羰基化合物及其制备方法和应用
EP2868348A1 (en) * 2013-11-04 2015-05-06 Universität Zürich CO-releasing compounds & formulations thereof useful for inducing mitochondrial biogenesis and tissue repair
CN103920456B (zh) * 2014-03-25 2015-12-30 陕西师范大学 基于天然粘土的一氧化碳释放材料及其制备方法
DE102014008537A1 (de) * 2014-06-04 2015-12-17 Friedrich-Schiller-Universität Jena Wasserlösliche manganbasierte Kohlenstoffmonoxid freisetzende Moleküle, deren Verwendung und Verfahren zu deren Herstellung
CA2950007A1 (en) 2014-06-09 2015-12-17 Georgia State University Research Foundation, Inc. Carbon monoxide-releasing molecules for therapeutic applications and methods of making and using thereof
WO2017007955A1 (en) 2015-07-07 2017-01-12 The Research Foundation For The State University Of New York Use of amine carboxyboranes as therapeutic delivery of carbon monoxide and as general drug delivery system in the presence of reactive oxygen species
CN107625954A (zh) * 2016-07-19 2018-01-26 上海本素医药科技有限公司 含一氧化碳的血红蛋白制剂及其在抗炎症中的应用
WO2018093924A1 (en) 2016-11-16 2018-05-24 Georgia State University Research Foundation, Inc. Carbon monoxide-releasing molecules and therapeutic applications thereof
US11685711B2 (en) 2017-08-09 2023-06-27 Georgia State University Research Foundation, Inc. Carbon monoxide-releasing molecules triggered by physiological stimuli
US10500217B2 (en) 2018-04-30 2019-12-10 Leslie Ray Matthews, M.D., Llc Vitamin D3, heat shock proteins, and glutathione for the treatment of chronic inflammation and chronic diseases
CN110585215B (zh) * 2019-09-19 2023-06-02 中山大学 氯化血红素及其复合物在医药中的新应用
JP7588861B2 (ja) * 2020-01-27 2024-11-25 学校法人同志社 一酸化炭素の定量方法及び一酸化炭素測定用キット
GB202004514D0 (en) 2020-03-27 2020-05-13 Inst De Medicina Molecular Joaeo Lobo Antunes Treatment of Immunosuppressive Cancer
WO2022055991A1 (en) * 2020-09-08 2022-03-17 The Brigham And Women's Hospital, Inc. Therapeutic carbon monoxide formulations
WO2022109086A1 (en) * 2020-11-18 2022-05-27 Proterris, Inc. Carbon monoxide releasing molecules and pharmaceutical compositions and uses thereof
CN113620983B (zh) * 2021-09-02 2022-05-27 山西大学 一种光控有机co供体分子及其制备方法和应用
CN115010939B (zh) * 2022-04-22 2023-04-28 深圳先进技术研究院 一种响应释放一氧化碳的羰基铁载体及其制备方法和应用
CN118105489A (zh) * 2024-02-05 2024-05-31 温州医科大学附属口腔医院 基于CO和AIEgens的协同抗菌纳米平台及其制备方法和应用
CN119385952B (zh) * 2025-01-02 2025-04-04 合肥市第一人民医院 可自释放co的纳米组装体、其制备方法及应用

Family Cites Families (135)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2870180A (en) * 1955-10-13 1959-01-20 Ethyl Corp Process for the preparation of hydrocarbon manganese carbonyl compounds
US3065250A (en) 1960-05-13 1962-11-20 Hercules Powder Co Ltd Nitrile-metal carbonyl complexes
US3278570A (en) * 1961-04-11 1966-10-11 Ethyl Corp Molybdenum pentacarbonyl compounds and process for preparing same
US3452079A (en) 1964-06-15 1969-06-24 Merck & Co Inc Acetic acid type compounds
GB1118728A (en) 1966-04-28 1968-07-03 James Kaye Improvements in or relating to the shaping of thermoplastic sheeting
CH536294A (de) * 1968-09-13 1973-04-30 Schering Ag Verfahren zur Herstellung von racemischen und optisch aktiven 4,6-Dichlor-4,6-östradienen
US3829504A (en) * 1970-06-04 1974-08-13 Int Flavors & Fragrances Inc Novel di-lower alkyl and lower alkylene acetals of 2-and 3-phenyl-pentenals
US3694232A (en) * 1970-06-04 1972-09-26 Int Flavors & Fragrances Inc Flavoring methods and compositions containing 3-phenyl pentenals
US3980583A (en) * 1974-02-19 1976-09-14 Mobil Oil Corporation Complexed metals bonded to inorganic oxides
NL7802482A (nl) * 1977-03-17 1978-09-19 Klosa Josef Preparaat voor de profylaxis en therapie van acne vulgaris en werkwijze voor de profylaxis en therapie van acne vulgaris met behulp van pyridinaldehyden.
US4312989A (en) * 1979-08-21 1982-01-26 The United States Of America As Represented By The Secretary Of The Army Pharmacologically active amine boranes
DE3070534D1 (en) 1979-12-21 1985-05-23 Univ Duke Pharmacologically active amine-carboxyboranes
US4322411A (en) * 1980-04-25 1982-03-30 Burroughs Wellcome Co. Anti-inflammatory nucleosides
US4613621A (en) * 1981-09-18 1986-09-23 Hoerrmann Wilhelm Fatty aldehydes and acids in the treatment of neurological and inflammatory diseases
DE3139358C2 (de) 1981-10-02 1984-06-07 Dragoco Gerberding & Co Gmbh, 3450 Holzminden Verwendung von 1,1-Di(C↓1↓-C↓6↓-alkyl)-2-phenyl-ethan-Derivaten als Riechstoffe
US4535167A (en) 1981-12-14 1985-08-13 Merck & Co. Inc. Chiral, N-protected, N-substituted α-amino acids
US4649151A (en) * 1982-09-27 1987-03-10 Health Research, Inc. Drugs comprising porphyrins
GB8407557D0 (en) * 1984-03-23 1984-05-02 Hayward J A Polymeric lipsomes
US4647555A (en) 1984-10-25 1987-03-03 The United States Of America As Represented By The Secretary Of The Army Esters of boron analogues of amino acids
US4657902A (en) 1985-03-25 1987-04-14 The Rockefeller University Therapeutic use of tin mesoporphyrin
US4709083A (en) * 1986-05-19 1987-11-24 The United States Of America As Represented By The Secretary Of The Army Method of making boron analogues
US4699903A (en) 1986-06-20 1987-10-13 The Rockefeller University Therapeutic use of tin diiododeuteroporphyrin
US4668670A (en) * 1986-06-20 1987-05-26 The Rockefeller University Tin diiododeuteroporphyrin and therapeutic use thereof
US4792452A (en) 1987-07-28 1988-12-20 E. R. Squibb & Sons, Inc. Controlled release formulation
JPH0670025B2 (ja) * 1987-08-07 1994-09-07 鐘紡株式会社 ベンゾチアゾ−ル誘導体および該化合物を有効成分とする抗リウマチ剤
US5350767A (en) * 1987-11-19 1994-09-27 Aktiebolaget Draco Derivatives of cysteine
US4938949A (en) * 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US5086060A (en) 1989-07-25 1992-02-04 Eastman Kodak Company Compound and method for treating skin for acne or psoriasis
HUT62193A (en) 1989-07-25 1993-04-28 Eastman Kodak Co Process for producing pharmaceutical composition improving the effect of photoageing
US5010073A (en) * 1989-10-05 1991-04-23 The Rockefeller University Use of liposomes as carriers for metalloporphyrins
US5362732A (en) 1989-12-20 1994-11-08 University Of North Carolina At Chapel Hill Boronated compounds
HU211084B (en) 1990-04-20 1995-10-30 Brezo Process for producing oral pharmaceutical composition of bone strengthening activity
DE4014762A1 (de) 1990-05-05 1991-11-07 Martin Prof Dr Wenzel Verbindungen zur strahlentherapie oder diagnostik durch absorption von moessbauer-strahlung
WO1992003402A1 (fr) 1990-08-24 1992-03-05 Firmenich Sa Compose cetonique polycyclique et son utilisation a titre d'ingredient parfumant
US5102670A (en) 1990-09-14 1992-04-07 Abraham Nader G Method for treating eye disorders by reducing 12(r)-hydroxyeicosatetraenoic acid and 12(r)-dihydroxyeicosatrienoic acid levels
US5254706A (en) * 1991-05-10 1993-10-19 Boron Biologicals, Inc. Process of making phosphite-borane compounds
WO1993005795A1 (en) * 1991-09-13 1993-04-01 Boron Biologicals, Inc. Method of combatting osteoporosis and other disease states in mammalian subjects, utilizing organic boron compounds
US5621100A (en) 1992-07-24 1997-04-15 Cephalon, Inc. K-252a derivatives for treatment of neurological disorders
GB2271351A (en) 1992-10-08 1994-04-13 Merck Patent Gmbh Carbocyclyl-phenyl-pyrazines and liquid crystalline media
GB9221327D0 (en) 1992-10-10 1992-11-25 Harden Richard C Letter receptacle
IT1256450B (it) 1992-11-26 1995-12-05 Soldato Piero Del Esteri nitrici con attivita' farmacologica e procedimento per la loro preparazione
AU6523194A (en) 1993-03-26 1994-10-24 Biorelease Technologies, Inc. Compositions including heme-containing proteins and methods relating thereto
FR2707085B1 (fr) 1993-06-30 1995-08-18 Adir Nouveaux dérivés d'alpha amino acides, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
US6284752B1 (en) * 1993-08-25 2001-09-04 Anormed Inc. Pharmaceutical compositions comprising metal complexes
US6417182B1 (en) * 1993-08-25 2002-07-09 Anormed Inc. Pharmaceutical compositions comprising metal complexes
GB9317686D0 (en) * 1993-08-25 1993-10-13 Johnson Matthey Plc Pharmaceutical compositions
US5811463A (en) * 1993-10-06 1998-09-22 University Of British Columbia Compositions and method for relaxing smooth muscles
CA2173582C (en) 1993-10-06 2006-11-28 Piero Del Soldato Nitric esters having anti-inflammatory and/or analgesic activity and process for their preparation
US5631284A (en) 1993-10-06 1997-05-20 University Of British Columbia Compositions and methods for relaxing smooth muscles
US6051576A (en) 1994-01-28 2000-04-18 University Of Kentucky Research Foundation Means to achieve sustained release of synergistic drugs by conjugation
US5891689A (en) 1994-04-12 1999-04-06 Innovir Laboratories, Inc. Heme-bearing microparticles for targeted delivery of drugs
KR100387359B1 (ko) 1994-05-10 2003-08-27 니콕스 에스. 에이. 항-염증성,비알러지성및항-혈전성을가지는니트로화합물들과그들의조성물들
DE4421433C1 (de) * 1994-06-18 1995-06-08 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit Wirkstoffen, die Kohlenmonoxid-Quellen darstellen, Verfahren zu seiner Herstellung und seine Verwendung
US5447939A (en) 1994-07-25 1995-09-05 Glasky; Alvin J. Carbon monoxide dependent guanylyl cyclase modifiers and methods of use
US5801184A (en) * 1994-07-25 1998-09-01 Glasky; Alvin J. Carbon monoxide dependent guanylyl cyclase modifiers and methods of use
US6338963B1 (en) * 1994-07-25 2002-01-15 Neotherapeutics, Inc. Use of carbon monoxide dependent guanylyl cyclase modifiers to stimulate neuritogenesis
CA2195302A1 (en) 1994-07-25 1996-02-08 Alvin J. Glasky Carbon monoxide dependent guanylyl cyclase modifiers
CA2132690A1 (en) 1994-09-22 1996-03-23 Dean Willis Control and modulation of inflammatory response in humans in need of such control and modulation
US6066333A (en) 1994-09-22 2000-05-23 William Harvey Research Limited Pharmaceutical control of inflammation
US5664563A (en) 1994-12-09 1997-09-09 Cardiopulmonary Corporation Pneumatic system
US5670664A (en) 1995-09-08 1997-09-23 University Of Maryland Biotechnology Institute Photosensitive organic compounds that release carbon monoxide upon illumination
DE19540475A1 (de) 1995-10-20 1997-04-24 Schering Ag Chirale Methylphenyloxazolidinone
US5767157A (en) * 1996-01-16 1998-06-16 Van Moerkerken; Arthur Arthritic pain prevention method and compositions
IT1276071B1 (it) 1995-10-31 1997-10-24 Nicox Ltd Compositi ad attivita' anti-infiammatoria
US20020193363A1 (en) * 1996-02-26 2002-12-19 Bridger Gary J. Use of nitric oxide scavengers to modulate inflammation and matrix metalloproteinase activity
DE69734983T2 (de) * 1996-03-20 2006-09-07 President And Fellows Of Harvard College, Cambridge Triarylmethanverbindungen zur behandlung von krebs, aktinischer keratose und kaposisarkom
US5888982A (en) 1996-04-01 1999-03-30 President And Fellows Of Harvard College Regulation of vascular smooth muscle cell heme oxygenase-1
ES2267141T3 (es) 1996-04-05 2007-03-01 The General Hospital Corporation Tratamiento de una hemoglobinopatia.
US5756492A (en) * 1996-09-09 1998-05-26 Sangstat Medical Corporation Graft survival prolongation with porphyrins
US8128963B2 (en) * 1996-09-27 2012-03-06 The Trustees Of Columbia University In The City Of New York Methods for treating ischemic disorders using carbon monoxide
JP2001501612A (ja) 1996-09-27 2001-02-06 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク 虚血性疾患を治療する方法及び発作後の症状を改善する方法
IT1295694B1 (it) 1996-11-14 1999-05-27 Nicox Sa Nitrossi derivati per la preparazione di medicamenti ad attivita antitrombinica
KR20000075681A (ko) 1997-02-26 2000-12-26 그레이엄 브레레톤, 레슬리 에드워즈 메탈로프로테아제 억제제로서의 후위 히드록사메이트 유도체
EP0879606A1 (en) 1997-04-25 1998-11-25 Paul Scherrer Institut Method for the preparation of facial metal tricarbonyl compounds and their use in the labelling of biologically active substrates
US6344178B1 (en) * 1997-04-25 2002-02-05 Mallinckrodt Inc. Method for the preparation of facial metal tricarbonyl compounds and their use in the labelling of biologically active substrates
IT1292377B1 (it) * 1997-06-19 1999-02-08 Nicox Sa Composizioni farmaceutiche a base di prostaglandine
IT1292426B1 (it) 1997-06-27 1999-02-08 Nicox Sa Sali nitrati di ace-inibitori
IT1301759B1 (it) 1998-06-19 2000-07-07 Nicox Sa Sali nitrati di farmaci antiipertensivi
US6203991B1 (en) 1998-08-21 2001-03-20 The Regents Of The University Of Michigan Inhibition of smooth muscle cell migration by heme oxygenase I
AU6427299A (en) 1998-10-13 2000-05-01 Brown University Research Foundation Substituted perhalogenated phthalocyanines
ID29488A (id) * 1998-10-23 2001-08-30 Procter & Gamble Keharuman serasi dan kepustakaan keharuman aldehid dan keton
WO2000036113A2 (en) 1998-12-17 2000-06-22 Sangstat Medical Corporation Extending graft survival by heme oxygenase-i expression induced immunomodulation
US6025394A (en) * 1999-01-29 2000-02-15 Cell Pathways, Inc. Method for treating patients with acne by administering substituted sulfonyl indenyl acetic acids, amides and alcohols
US6673908B1 (en) * 1999-02-22 2004-01-06 Nuvelo, Inc. Tumor necrosis factor receptor 2
US20020049190A1 (en) 1999-03-19 2002-04-25 Bridger Gary J. Pharmaceutical compositions comprising metal complexes
IL145552A0 (en) 1999-03-23 2002-06-30 Univ James Cook Organ arrest, protection and preservation
US7678390B2 (en) 1999-04-01 2010-03-16 Yale University Carbon monoxide as a biomarker and therapeutic agent
IT1311924B1 (it) 1999-04-13 2002-03-20 Nicox Sa Composti farmaceutici.
US6251927B1 (en) * 1999-04-20 2001-06-26 Medinox, Inc. Methods for treatment of sickle cell anemia
IT1314184B1 (it) 1999-08-12 2002-12-06 Nicox Sa Composizioni farmaceutiche per la terapia di condizioni di stressossidativo
GB9920566D0 (en) 1999-08-31 1999-11-03 Univ London Screen for axon viability
JP4778654B2 (ja) * 1999-10-05 2011-09-21 マリンクロッド・インコーポレイテッド 遷移金属カルボニル錯体調製用の一酸化炭素供給源
US6484747B2 (en) 2000-04-05 2002-11-26 Jerry S. Bridgers Medical gas utility stand
US6518269B1 (en) * 2000-07-28 2003-02-11 University Of Arizona Foundation Cancer treatment
US6645938B2 (en) * 2000-10-10 2003-11-11 Zymogenetics, Inc. Protection against ischemia and reperfusion injury
US20040122091A1 (en) * 2000-10-11 2004-06-24 Esperion Therapeutics, Inc. Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses
FR2816212A1 (fr) 2000-11-03 2002-05-10 Air Liquide Sante Int Utilisation de monoxyde de carbone (co) dans le traitement des inflammations du systeme cardiovasculaire
EP1381354A2 (en) 2001-03-30 2004-01-21 Sangstat Medical Corporation Carbon monoxide generating compounds for treatment of vascular, inflammatory and immune disorders
DE50200711D1 (de) 2001-04-07 2004-09-02 Schmalz Hans Guenther Substanzen zur therapie von erkrankungen, die durch hochproliferierende zellen verursacht werden
ITMI20010985A1 (it) 2001-05-15 2002-11-15 Nicox Sa Farmaci per il morbo di alzheimer
GB0111872D0 (en) * 2001-05-15 2001-07-04 Northwick Park Inst For Medica Therapeutic agents and methods
EP2033514A3 (en) * 2001-06-21 2009-04-29 Beth Israel Deaconess Medical Center, Inc. Carbon Monoxide Improves Outcomes in Cell and Organ Transplants and Suppresses Apoptosis
US8246969B2 (en) * 2001-11-16 2012-08-21 Skinmedica, Inc. Compositions containing aromatic aldehydes and their use in treatments
US20030157154A1 (en) * 2002-01-04 2003-08-21 Bryan Fuller Compositions containing hydroxy aromatic aldehydes and their use in treatments
US7968605B2 (en) * 2002-02-04 2011-06-28 ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda. Methods for treating inflammatory disease by administering aldehydes and derivatives thereof
NZ534912A (en) * 2002-02-04 2007-08-31 Alfama Investigacao E Desenvol supramolecule aggregate comprising CO containing organometallic or transition metal complex and anti-inflammatory agent or biphosphonate phosphonate derivative
US20080026984A1 (en) * 2002-02-04 2008-01-31 Alfama - Investigacao E Desenvolvimento De Productos Farmaceuticos Lda Methods for treating inflammatory disease by administering aldehydes and derivatives thereof
WO2003067598A2 (en) 2002-02-06 2003-08-14 Koninklijke Philips Electronics N.V. Reading circuit for reading a memory cell
SG148850A1 (en) 2002-02-13 2009-01-29 Beth Israel Hospital Methods of treating vascular disease
US20040143025A1 (en) * 2002-04-01 2004-07-22 Roland Buelow Carbon monoxide generating compunds for treatment of vascular, inflammatory and immune disorders
MXPA04010242A (es) 2002-04-15 2005-06-08 Univ Pittsburgh Metodos para tratar enterocolitis necrotizante.
PL373002A1 (en) 2002-04-15 2005-08-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Methods of treating ileus
ITMI20020960A1 (it) * 2002-05-07 2003-11-07 Univ Degli Studi Milano Aldeidi lineari poliinsature e loro derivati ad attivita' antiradicalica e antitumorale
KR20040106515A (ko) 2002-05-09 2004-12-17 예일 유니버시티 바이오마커 및 치료제로서 일산화탄소
DK1505990T3 (da) 2002-05-17 2011-11-21 Univ Yale Fremgangsmåder til behandling af hepatitis
EA200401622A1 (ru) 2002-06-05 2005-06-30 Йейл Юниверсити Способы лечения ангиогенеза, роста опухолей и метастазов
HRP20041204A2 (en) 2002-06-21 2005-06-30 University Of Pittsburgh Of The Commonwealth Systebeth Israel Deaconess Medical Center Pharmaceutical use of nitric oxide, heme oxygenase-1 and products of heme degradation
ES2315526T3 (es) 2002-09-09 2009-04-01 Nektar Therapeutics Al, Corporation Metodo para preparar derivados polimericos solubles en agua que llevan un acido carboxilico terminal.
JP4323271B2 (ja) 2002-09-27 2009-09-02 花王株式会社 バレロラクトン化合物及び香料組成物
CA2504604A1 (en) 2002-11-07 2004-05-27 Timothy R. Billiar Treatment for hemorrhagic shock
GB2395432B (en) 2002-11-20 2005-09-14 Northwick Park Inst For Medica Therapeutic delivery of carbon monoxide to extracorporeal and isolated organs
GB2395431A (en) 2002-11-20 2004-05-26 Northwick Park Inst For Medica Combination of a metal carbonyl compound and a guanylate cyclase stimulant or stabilizer for the therapeutic delivery of carbon monoxide
US7670631B2 (en) 2003-03-12 2010-03-02 ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda. Method for the prevention of malaria infection of humans by hepatocyte growth factor antagonists
US7709534B2 (en) * 2003-04-28 2010-05-04 University Of The West Indies Method of treating strongyloides infections and medicaments therefor
WO2005013691A1 (en) 2003-08-04 2005-02-17 Hemocorm Limited Use of boranocarbonates for the therapeutic delivery of carbon monoxide
CA2560525A1 (en) 2004-03-18 2005-09-29 The University Court Of The University Of Glasgow Immunosuppressive cytokine
CN1993454A (zh) 2004-06-24 2007-07-04 弗莱克查尔公司 新颖的醛式麝香及其衍生物
US8148356B2 (en) 2005-08-24 2012-04-03 Cumberland Pharmaceuticals, Inc. Acetylcysteine composition and uses therefor
WO2007073226A1 (en) 2005-12-20 2007-06-28 Alfama - Investigação E Desenvolvimento De Produtos Farmacêuticos Lda Method for treating a mammal by administration of a compound having the ability to release co
WO2007073225A1 (en) * 2005-12-20 2007-06-28 Alfama - Investigação E Desenvolvimento De Produtos Farmacêuticos Lda. Molybdenum carbonyl complexes for treating rheumatoid arthritis and other inflammatory diseases
GB0601394D0 (en) 2006-01-24 2006-03-01 Hemocorm Ltd Therapeutic delivery of carbon monoxide
GB0613362D0 (en) 2006-07-05 2006-08-16 Hemocorm Ltd Therapeutic delivery of carbon monoxide
AU2007328549A1 (en) 2006-12-06 2008-06-12 Alfama - Investigacao E Desenvolvimento De Produtos Farmaceuticos Lda Methods for treating inflammatory disease by administering aldehydes and derivatives thereof
JP2010525055A (ja) 2007-04-24 2010-07-22 アルファーマ−インベスティガシオ エ デセンボルビメント デ プロデュトス ファルマセウティコス エレデア． 一酸化炭素による感染症の処置
US20110038955A1 (en) 2007-07-24 2011-02-17 Alfama - Investigacao E Desenvolvimento De Produtos Farmaceuticos, Lda. Prevention of gastric ulcer by carbon monoxide

Also Published As

Publication number Publication date
US9023402B2 (en) 2015-05-05
AU2009202682A1 (en) 2009-07-23
US20110237546A1 (en) 2011-09-29
US7011854B2 (en) 2006-03-14
BR0307420A (pt) 2004-12-21
AU2003208525B2 (en) 2009-04-02
WO2003066067A3 (en) 2004-02-05
NZ534912A (en) 2007-08-31
AU2003208525A1 (en) 2003-09-02
US20060148900A1 (en) 2006-07-06
WO2003066067A2 (en) 2003-08-14
US20040067261A1 (en) 2004-04-08
US20060233890A1 (en) 2006-10-19
EP2042181A1 (en) 2009-04-01
CA2475209A1 (en) 2003-08-14
JP2005519928A (ja) 2005-07-07
EP1476168A2 (en) 2004-11-17
ZA200406711B (en) 2006-05-31
EP2319518A1 (en) 2011-05-11
CN1646140A (zh) 2005-07-27
US7964220B2 (en) 2011-06-21
AU2003208525B9 (en) 2009-08-27

Similar Documents

Publication Publication Date Title
RU2004126950A (ru) Использование выделяющих co соединений при изготовлении лекарственного средства для лечения воспалительных заболеваний
US8933255B2 (en) Nutraceuticals containing nitro fatty acids
JP2008519812A5 (ru)
JP2007530523A5 (ru)
KR20180021784A (ko) 피부병의 치료를 위한 니코틴아미드 리보시드 및 프테로스틸벤 조성물 및 방법
JP2002532432A5 (ru)
JP2005537268A5 (ru)
AR035071A1 (es) Compuestos para el tratamiento de la disfuncion endotelial; metodo para producir a dichos compuestos farmaceuticos; uso de dichos compuestos para la manufactura de un medicamento
JPH05163139A (ja) 抗動脈硬化剤
ME02149B (me) FORMULACIJE l METODE ZA LEČENJE AMILOIDOZE
BR9807319A (pt) Microgrânulos com liberação controlada, para administração oral, contendo cisplatina, processo de preparação dos mesmos, preparação farmacêutica, e, utilização dos microgrânulos.
JP2004517843A5 (ru)
RU2004132856A (ru) Фармацевтический препарат с модифицированным высвобождением
AR046410A1 (es) Composiciones farmaceuticas para la liberacion modificada de modafinilo
JP2002534379A5 (ru)
RU99119233A (ru) Фармацевтические композиции, содержащие ибупрофен и домперидон для лечения мигрени
JP2004533462A (ja) 血管症の治療のための有機ナイトレートをベースとする化合物
JP2002522462A5 (ru)
RU2007127127A (ru) 4-циклоалкил-замещенные производные тетрагидрохинолина и их применение в качестве лекарств
CN1291891A (zh) 治疗肺慢性阻塞性疾病的方法
TW200724138A (en) Substituted carboxylic acid derivatives for the treatment of diabetes and lipid disorders, their preparation and use
JPWO2019236757A5 (ru)
TW577741B (en) Novel pharmaceutical combination for treating pain comprising paracetamol and buspirone
JPWO2007086395A1 (ja) 光線力学的療法用キット
JPS63501360A (ja) 血栓性および血栓塞栓性疾患の治療のためのプロスタサイクリン、その類縁体またはプロスタグランジンおよびトロンボキサン類縁体

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20070820